首页 | 本学科首页   官方微博 | 高级检索  
检索        


Influenza in Latin America: A report from the Global Influenza Initiative (GII)
Institution:1. State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong SAR, China;2. Clinical Microbiology, University Hospitals Leicester, Level 5 Sandringham Building, Leicester Royal Infirmary, Infirmary Square, Leicester LE1 5WW, UK;3. Cardiovascular Biomedical Research Unit, University of Leicester, Leicester, UK;4. Faculty of Medicine, American University of Beirut, Beirut, Lebanon;5. Child Health Research Centre, The University of Queensland, Brisbane, Australia;6. Children''s Health Queensland, Brisbane, Australia;7. National Influenza Center, Virology Unit, Institut Pasteur de Madagascar, Antananarivo 101, Madagascar;8. Alberta Provincial Laboratory for Public Health, University of Alberta, Edmonton, AB, Canada;9. Department of Pathology, Dalhousie University, Halifax, NS, Canada;10. Department of Microbiology, The Chinese University of Hong Kong SAR, Hong Kong, China;11. Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;12. Molecular Diagnosis Centre, National University Hospital, Singapore;13. Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;14. Department of Pediatrics, Erasmus Medical Centre, Rotterdam, Netherlands;15. ViroScience, Erasmus Medical Centre, Rotterdam, Netherlands;p. Pathology Department, University of Otago, Christchurch, New Zealand;q. Institute of Biomedicine, University of Turku, Finland;r. Clinical Microbiology, Turku University Hospital, Turku, Finland;s. British Columbia Centre for Disease Prevention and Control, Vancouver, BC, Canada;t. Government of the Northwest Territories, Yellowknife, NT, Canada;u. Department of Pathology, Addenbrookes Hospital, Cambridge, UK;v. Virus Research Center, Sendai Medical Center, Sendai, Japan;w. Laboratory of Virology, National Center for Communicable Diseases, Ulaanbaatar, Mongolia;x. Department of Parasitology, Microbiology and Immunology, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil;y. National Reference Laboratory, Kigali, Rwanda;z. NSWHP-ICPMR, Westmead Hospital, Sydney, Australia;11. Pathology and Infectious Diseases, University of Sydney, Sydney, Australia
Abstract:The Global Influenza Initiative (GII) is a global expert group that aims to raise acceptance and uptake of influenza vaccines globally and provides recommendations and strategies to address challenges at local, national, regional, and global levels. This article provides a consolidated estimation of disease burden in Latin America, currently lacking in published literature, and delivers the GII recommendations specific to Latin America that provide guidance to combat existing vaccination challenges.While many countries worldwide, especially in the tropics and subtropics, do not have a seasonal influenza policy, 90% of Latin American countries have a seasonal influenza policy in place. Local governments in the Latin American countries and The Pan American Health Organization’s Technical Advisory Group on Vaccine-preventable Diseases play a major role in improving the vaccination coverage and reducing the overall disease burden. Influenza seasonality poses the biggest challenge in deciding on optimal timing for vaccination in Latin America, as in temperate climates seasonal influenza activity peaks during the winter months (November–February and May–October) in the northern and southern hemispheres, respectively, while in the tropics and subtropical regions it usually occurs throughout the year, but especially during the rainy season. Besides this, vaccine mismatch with circulating strains, misconception concerning influenza vaccine effectiveness, and poor disease and vaccine awareness among the public are also key challenges that need to be overcome. Standardization of clinical case definitions is important across all Latin American countries. Surveillance (mostly passive) has improved substantially in the Latin American countries over the past decade, but more is still required to better understand the disease burden and help inform policies.
Keywords:Influenza  Latin America  Epidemiology  Surveillance  Vaccination  Global Influenza Initiative  EW"}  {"#name":"keyword"  "$":{"id":"k0040"}  "$$":[{"#name":"text"  "_":"epidemiology week  GII"}  {"#name":"keyword"  "$":{"id":"k0050"}  "$$":[{"#name":"text"  "_":"Global Influenza Initiative  GISRS"}  {"#name":"keyword"  "$":{"id":"k0060"}  "$$":[{"#name":"text"  "_":"Global Influenza Surveillance and Response System  HCW"}  {"#name":"keyword"  "$":{"id":"k0070"}  "$$":[{"#name":"text"  "_":"healthcare worker  ILI"}  {"#name":"keyword"  "$":{"id":"k0080"}  "$$":[{"#name":"text"  "_":"influenza-like illness  PAHO"}  {"#name":"keyword"  "$":{"id":"k0090"}  "$$":[{"#name":"text"  "_":"Pan American Health Organization  QIV"}  {"#name":"keyword"  "$":{"id":"k0100"}  "$$":[{"#name":"text"  "_":"quadrivalent influenza vaccine  SARI"}  {"#name":"keyword"  "$":{"id":"k0110"}  "$$":[{"#name":"text"  "_":"severe acute respiratory illness  TAG"}  {"#name":"keyword"  "$":{"id":"k0120"}  "$$":[{"#name":"text"  "_":"Technical Advisory Group on Vaccine-preventable Diseases  TIV"}  {"#name":"keyword"  "$":{"id":"k0130"}  "$$":[{"#name":"text"  "_":"trivalent inactivated influenza vaccine  WHO"}  {"#name":"keyword"  "$":{"id":"k0140"}  "$$":[{"#name":"text"  "_":"World Health Organization
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号